Nature's Sunshine Products (NATR) 10-Q8 Nov 182018 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 01, 2018
Document and Entity Information
Entity Registrant Name	NATURES SUNSHINE PRODUCTS INC
Entity Central Index Key	275,053
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		19,203,682
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 47,859	$ 42,910
Accounts receivable, net of allowance for doubtful accounts of $523 and $395, respectively	8,106	8,888
Assets held for sale	0	998
Inventories	43,041	44,047
Prepaid expenses and other	5,978	5,666
Total current assets	104,984	102,509
Property, plant and equipment, net	65,531	69,106
Investment securities - trading	1,602	1,980
Intangible assets, net	740	709
Deferred income tax assets	7,584	8,283
Other assets	11,086	12,608
Total assets	191,527	195,195
Current liabilities:
Accounts payable	4,240	4,215
Accrued volume incentives and service fees	18,628	18,774
Accrued liabilities	32,801	24,980
Deferred revenue	2,014	3,348
Income taxes payable	1,754	1,834
Related party note payable	1,523	506
Total current liabilities	60,960	53,657
Liability related to unrecognized tax benefits	2,192	4,633
Long-term debt and revolving credit facility	1,836	13,181
Deferred compensation payable	1,602	1,980
Long-term deferred income tax liabilities	763	770
Other liabilities	688	1,242
Total liabilities	68,041	75,463
Commitments and contingencies
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 19,204 and 18,919 shares issued and outstanding, respectively	133,069	131,525
Retained earnings (accumulated deficit)	844	(2,072)
Noncontrolling interest (deficit)	(41)	411
Accumulated other comprehensive loss	(10,386)	(10,132)
Total shareholders’ equity	123,486	119,732
Total liabilities and shareholders’ equity	$ 191,527	$ 195,195

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 523	$ 395
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	19,204,000	18,919,000
Common stock, shares outstanding (in shares)	19,204,000	18,919,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net sales	$ 88,828	$ 89,301	$ 267,436	$ 253,743
Cost of sales	23,161	23,505	70,152	66,430
Gross profit	65,667	65,796	197,284	187,313
Operating expenses:
Volume incentives	30,511	30,716	93,365	87,987
Selling, general and administrative	31,643	32,926	97,339	95,098
Operating income	3,513	2,154	6,580	4,228
Other income (loss), net	(353)	193	(1,420)	1,909
Income before provision for income taxes	3,160	2,347	5,160	6,137
Provision (benefit) for income taxes	1,821	(1)	3,550	2,346
Net income	1,339	2,348	1,610	3,791
Net loss attributable to noncontrolling interests	(158)	(95)	(452)	(625)
Net income attributable to common shareholders	$ 1,497	$ 2,443	$ 2,062	$ 4,416
Basic and diluted net income per common share:
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.08	$ 0.13	$ 0.11	$ 0.23
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.08	$ 0.13	$ 0.11	$ 0.23
Weighted average basic common shares outstanding (in shares)	19,164	18,897	19,094	18,873
Weighted average diluted common shares outstanding (in shares)	19,382	19,286	19,406	19,265
Dividends declared per common share (in dollars per share)	$ 0	$ 0	$ 0	$ 0.1

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 1,339	$ 2,348	$ 1,610	$ 3,791
Foreign currency translation gain (loss) (net of tax)	12	113	(254)	473
Net unrealized gains on investment securities (net of tax)	0	0	0	15
Total comprehensive income	$ 1,351	$ 2,461	$ 1,356	$ 4,279

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Retained Earnings (Accumulated Deficit)	Noncontrolling Interest (Deficit)	Accumulated Other Comprehensive Loss
Increase (Decrease) in Shareholders' Equity
Cumulative effect of change in accounting principle	$ 854		$ 854
Beginning balance, adjusted balance	$ 120,586	$ 131,525	(1,218)	$ 411	$ (10,132)
Beginning balance (in shares) at Dec. 31, 2017	18,919,000	18,919,000
Beginning balance at Dec. 31, 2017	$ 119,732	$ 131,525	(2,072)	411	(10,132)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,458	$ 1,458
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		285,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	86	$ 86
Net income (loss)	1,610		2,062	(452)
Other comprehensive loss	$ (254)				(254)
Ending balance (in shares) at Sep. 30, 2018	19,204,000	19,204,000
Ending balance at Sep. 30, 2018	$ 123,486	$ 133,069	$ 844	$ (41)	$ (10,386)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,610	$ 3,791
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for (recovery of) doubtful accounts	155	(22)
Depreciation and amortization	7,313	6,036
Share-based compensation expense	1,458	1,904
Gain on sale of property, plant and equipment	(4,000)	0
Deferred income taxes	650	245
Purchase of trading investment securities	(128)	(450)
Proceeds from sale of trading investment securities	610	102
Realized and unrealized gains on investments	(80)	(145)
Foreign exchange (gains) losses	1,250	(2,089)
Changes in assets and liabilities:
Accounts receivable	467	(3,115)
Inventories	462	(616)
Prepaid expenses and other current assets	(420)	(573)
Other assets	897	799
Accounts payable	88	(422)
Accrued volume incentives and service fees	169	4,240
Accrued liabilities	7,949	(621)
Deferred revenue	(1,334)	1,118
Income taxes payable	(32)	(847)
Liability related to unrecognized tax benefits	(2,501)	(1,815)
Deferred compensation payable	(378)	516
Net cash provided by operating activities	14,205	8,036
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(3,959)	(3,889)
Proceeds from sale of property, plant and equipment	5,072	522
Proceeds from sale/maturities of investments available for sale	0	1,776
Net cash provided by (used in) investing activities	1,113	(1,591)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of cash dividends	0	(1,848)
Principal payments of new revolving credit facility	(56,853)	0
Borrowings on new revolving credit facility	45,508	19,184
Net borrowings on previous revolving credit facility	0	(9,996)
Proceeds from related party borrowing	1,000	500
Net proceeds from the exercise of stock options	664	104
Payment of withholding taxes related to the vesting of restricted stock units	(578)	(521)
Net cash provided by (used in) financing activities	(10,259)	7,423
Effect of exchange rates on cash and cash equivalents	(110)	1,540
Net increase in cash and cash equivalents	4,949	15,408
Cash and cash equivalents at the beginning of the period	42,910	32,284
Cash and cash equivalents at the end of the period	47,859	47,692
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	3,700	3,874
Cash paid for interest	$ 220	$ 215

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Nature’s Sunshine Products, Inc., together with its subsidiaries (hereinafter referred to collectively as the “Company”), is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent distributors who use the products themselves or resell them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The Company consolidates the joint ventures in Hong Kong and China in its consolidated financial statements, with another party’s interest presented as noncontrolling interest. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the Company’s financial information as of September 30, 2018 , and for the three and nine -month periods ended September 30, 2018 and 2017 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2018 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 . Noncontrolling Interests Noncontrolling interests decreased as a result of the net loss attributable to the noncontrolling interests by $0.5 million and $0.6 million during the nine months ended September 30, 2018 and 2017 , respectively. As of September 30, 2018 and December 31, 2017 , noncontrolling deficits were $41,000 and noncontrolling interests were $0.4 million , respectively. Restructuring Related Accruals and Expenses Accrued severance and rent costs were $0.3 million and $0.8 million as of September 30, 2018 and December 31, 2017 , respectively. The Company did not record any additional restructuring related expenses during the three and nine months ended September 30, 2018 and 2017 , respectively. Chief Executive Officer Related Transition Costs During the second quarter of 2018, the Company announced the pending retirement of its Chief Executive Officer. As a result, the Company recorded $17,000 and $1.5 million of transition -related expenses during the three- and nine-month periods ended September 30, 2018 . As of September 30, 2018 , accrued transition costs were $1.1 million . Recent Accounting Pronouncements The Company adopted the requirements of revenue recognition from Accounting Standards Update ( “ ASU ” ) 2014-09, Revenue from Contracts with Customers (“Topic 606”) effective January 1, 2018 under the modified retrospective approach. The cumulative effect of adopting Topic 606 on January 1, 2018 was a decrease to accumulated deficit of $0.9 million (net of tax). See Note 13 - Revenue Recognition for additional disclosure of the adoption of Topic 606. In January 2016, the Financial Accounting Standards Board ( “ FASB ” ) issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure requirements associated with the fair value of financial instruments. This update is effective for interim and annual periods beginning after December 15, 2017. The adoption of this ASU did not have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842): Accounting for Leases. This update specifies that lessees should recognize right-of-use assets and lease liabilities arising from leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and shall continue to depend on its classification as a finance or operating lease. The Company will adopt the ASU and related amendments on January 1, 2019 and expects to elect certain practical expedients permitted under the transition guidance. The Company will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and will not restate prior periods. Under the new guidance, the majority of the Company's leases will continue to be classified as operating. The Company continues to evaluate the potential impact of adoption of this ASU on its consolidated financial statements, and expects a significant gross-up of total assets and liabilities upon adoption. The adoption of this ASU is not expected to have a significant impact on the Company's Consolidated Statements of Income or Cash Flows. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update amends the scope of modification accounting surrounding share-based payment arrangements as issued in ASU 2016-09 by providing guidance on the various types of changes which would trigger modification accounting for share-based payment awards. ASU 2017-09 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The adoption of ASU 2017-09 did not have a material effect on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Effects from Accumulated Other Comprehensive Income. This update allows a reclassification of stranded tax effects, resulting from the Tax Cuts and Jobs Act 2017, from accumulated other comprehensive income to retained earnings. This ASU will be effective for annual periods beginning after December 15, 2018 with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the potential impact of this adoption on its condensed consolidated financial statements.

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): September 30, December 31, Raw materials $ 10,625 $ 9,522 Work in progress 1,937 2,153 Finished goods 30,479 32,372 Total inventories $ 43,041 $ 44,047

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
Property, Plant and Equipment	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment In August of 2018, the Company sold an eight -acre property in Provo, Utah for $2.7 million . The Company originally acquired the property with the intent to erect a building for the corporate headquarters and later decided to move the headquarters elsewhere. As the fair value of the property exceeded the carrying value, a net gain of $1.7 million was recognized during the three and nine months ended September 30, 2018 . In June of 2018, the Company sold a 29,300 square foot building in Mexico City, Mexico for $2.6 million . The Company previously utilized the building for offices as well as warehouse space and has since relocated to a more advantageous location. As the fair value of the property exceeded the carrying value, a net gain of $0 and $2.3 million were recognized during the three and nine months ended September 30, 2018 , respectively.

Investment Securities - Trading

Investment Securities - Trading	9 Months Ended
Investment Securities - Trading	Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]
Investment Securities - Trading	Investment Securities - Trading The Company’s trading securities portfolio totaled $1.6 million at September 30, 2018 , and $2.0 million at December 31, 2017 , and generated gains of $70,000 and $51,000 for the three months ended September 30, 2018 and 2017 , respectively, and $103,000 and $102,000 for the nine months ended September 30, 2018 and 2017 , respectively.

Revolving Credit Facility

Revolving Credit Facility	9 Months Ended
Revolving Credit Facility	Sep. 30, 2018
Debt Disclosure [Abstract]
Revolving Credit Facility	Revolving Credit Facility On July 11, 2017, the Company entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million , that matures on July 11, 2020 (the “Credit Agreement”). The Company pays interest on any borrowings under the Credit Agreement at LIBOR plus 1.25 percent ( 3.49 percent and 2.82 percent as of September 30, 2018 and December 31, 2017 ), and an annual commitment fee of 0.2 percent on the unused portion of the commitment. The Company is required to settle its net borrowings under the Credit Agreement only upon maturity, and as a result, has classified its outstanding borrowings as non-current on its condensed consolidated balance sheet as of September 30, 2018 . At September 30, 2018 , the outstanding balance under the Credit Agreement was $1.8 million . The Credit Agreement contains customary financial covenants, including financial covenants relating to the Company’s solvency, leverage, and minimum EBITDA. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, and merger, consolidation and the transfer of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by the Company’s manufacturing facility, accounts receivable balance, inventory balance and other assets. Effective June 30, 2018, the Company and Bank of America amended the Credit Agreement to modify certain financial covenants. As of September 30, 2018 , the Company was in compliance with the debt covenants set forth in the Credit Agreement.

Net Income Per Share

Net Income Per Share	9 Months Ended
Net Income Per Share	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and nine months ended September 30, 2018 and 2017 (dollar and share amounts in thousands, except for per share information): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Net income attributable to common shareholders $ 1,497 $ 2,443 $ 2,062 $ 4,416 Basic weighted average shares outstanding 19,164 18,897 19,094 18,873 Basic earnings per share attributable to common shareholders $ 0.08 $ 0.13 $ 0.11 $ 0.23 Diluted shares outstanding: Basic weighted-average shares outstanding 19,164 18,897 19,094 18,873 Stock-based awards 218 389 312 392 Diluted weighted-average shares outstanding 19,382 19,286 19,406 19,265 Diluted earnings per share attributable to common shareholders $ 0.08 $ 0.13 $ 0.11 $ 0.23 Dilutive shares excluded from diluted-per-share amounts: Stock options 105 294 105 294 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options 1,036 1,309 1,011 1,309 Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

Capital Transactions

Capital Transactions	9 Months Ended
Capital Transactions	Sep. 30, 2018
Equity [Abstract]
Capital Transactions	Capital Transactions Share-Based Compensation During the year ended December 31, 2012, the Company’s shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of the Company’s common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, the Company’s shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. The Company also maintains a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares. Stock Options The Company’s outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six , eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the nine -month period ended September 30, 2018 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2017 1,390 $ 12.20 Granted 50 8.43 Forfeited or canceled (227 ) 13.87 Exercised (99 ) 6.10 Options outstanding at September 30, 2018 1,114 12.23 During the nine months ended September 30, 2018 , the Company granted options to purchase 50,000 shares of common stock under the 2012 Stock Incentive Plan to members of the Company’s Board of Directors. These options were issued with an exercise price of $8.43 per share and a grant date fair value of $3.30 per share, with an expected life of five years, risk-free interest rate of 2.8 percent , and expected volatility of 38.8 percent . Share-based compensation expense from time-based stock options for the three-month periods ended September 30, 2018 and 2017 , was approximately $0.1 million and $(0.2) million , respectively. Share-based compensation expense from time-based stock options for the nine -month periods ended September 30, 2018 and 2017 , was approximately $0.2 million and $0.2 million , respectively. As of September 30, 2018 there was no unrecognized share-based compensation expense related to the grants described above as all outstanding options were vested. As of December 31, 2017 , the unrecognized share-based compensation expense related to the grants described above was $13,000 . At September 30, 2018 , the aggregate intrinsic value of outstanding and vested stock options to purchase 1,114,000 shares of common stock was $0.3 million . At December 31, 2017 , the aggregate intrinsic value of outstanding options to purchase 1,390,000 shares of common stock, the exercisable options to purchase 1,293,000 shares of common stock, and options to purchase 92,000 shares of common stock expected to vest was $0.9 million , $0.9 million and $0.0 million , respectively. For the nine -month periods ended September 30, 2018 and 2017 , the Company issued 99,000 and 9,000 shares of common stock upon the exercise of stock options at an average exercise price of $6.10 and $11.98 per share, respectively. The aggregate intrinsic value of options exercised during the nine -month periods ended September 30, 2018 and 2017 , was $0.4 million and $0.2 million , respectively. For the nine -month periods ended September 30, 2018 and 2017 , the Company recognized $0.1 million and $0.0 million of tax benefits from the exercise of stock options, respectively. As of September 30, 2018 and December 31, 2017 , the Company did not have any unvested performance-based stock options outstanding. Restricted Stock Units The Company’s outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 48 months from the RSU grant date, as well as performance-based RSUs, which vest either upon achieving cumulative annual net sales growth targets over a rolling one -year period or upon achieving earnings-per-share targets over a rolling one -year period or weighted-average share prices over a rolling 45 day period. RSUs granted to members of the Company’s Board of Directors are not issued until the expiration of a two -year restriction period following vesting. There were 71,000 and 96,000 vested RSUs as of September 30, 2018 and December 31, 2017 , respectively, that have been granted to members of the Company’s Board of Directors but remain subject to the two -year restriction period. RSU activity for the nine -month period ended September 30, 2018 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2017 728 $ 11.56 Granted 511 9.93 Forfeited (103 ) 12.17 Issued (243 ) 11.77 Restricted Stock Units outstanding at September 30, 2018 893 10.50 During the nine -month period ended September 30, 2018 , the Company granted 511,000 RSUs under the 2012 Incentive Plan to the Company’s Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and net sales and adjusted EBITDA performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $10.16 per share and vest in annual installments over a three -year period from the grant date or according to the restrictions for the Board of Directors noted above. The net sales and adjusted EBITDA earnings-per-share performance-based RSUs were issued with a weighted-average grant date fair value of $9.79 per share and vest upon achieving targets over a three -year period from the grant date. RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. The Finnerty Model proposes to estimate a discount for lack of marketability such as transfer restrictions by using an option pricing theory. The concept underpinning the Finnerty Model is that restricted stock cannot be sold over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 11.9 percent for a common share. Share-based compensation expense for RSUs for the three-month periods ended September 30, 2018 and 2017 , was approximately $0.3 million and $0.3 million , respectively. Share-based compensation expense from RSUs for the nine -month periods ended September 30, 2018 and 2017 , was approximately $1.3 million and $1.7 million , respectively. As of September 30, 2018 and December 31, 2017 , the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.4 million and $2.0 million , respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 1.5 years . The Company has not recognized any share-based compensation expense related to the net sales and earnings-per-share performance-based RSUs for the nine -month periods ended September 30, 2018 and 2017 . Should the Company attain all of the net sales metrics related to the net sales performance-based stock option grants, the Company would recognize up to $4.7 million of potential share-based compensation expense. The number of shares issued upon vesting of RSUs granted pursuant to the Company’s share-based compensation plans is net of the minimum statutory withholding requirements that the Company pays on behalf of its employees, which was 55,000 shares for the nine -month period ended September 30, 2018 . Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.

Segment Information

Segment Information	9 Months Ended
Segment Information	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Information	Segment Information The Company has four business segments. These business segments are components of the Company for which separate information is available and evaluated regularly by the chief executive officer in deciding how to allocate resources and in assessing relative performance. The Company’s four business segments are divided based on the different characteristics of their distributor and customer bases, distributor compensation plans and product formulations, as well as the internal organization of its officers and their responsibilities and business operations. Three business segments operate under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China), and one business segment operates under the Synergy® WorldWide brand. Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. The Company evaluates performance based on contribution margin (loss) by segment before consideration of certain inter-segment transfers and expenses. In the fourth quarter of 2017, the Company moved the reporting of its wholesale business, in which the Company sells its products to a locally managed entity independent of the Company that has distribution rights for the market, from the NSP China segment to the NSP Russia, Central and Eastern Europe segment. The net sales and contribution margin for the three and nine months ended September 30, 2017 were recast to reflect that change. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Net sales: NSP Americas $ 38,512 $ 41,301 $ 118,769 $ 125,367 NSP Russia, Central and Eastern Europe 8,841 7,681 27,799 23,286 Synergy WorldWide 34,497 34,470 103,034 92,146 NSP China 6,978 5,849 17,834 12,944 Total net sales 88,828 89,301 267,436 253,743 Contribution margin (1): NSP Americas 17,006 17,764 49,530 53,454 NSP Russia, Central and Eastern Europe 3,098 2,592 9,437 6,173 Synergy WorldWide 9,652 10,160 30,915 27,769 NSP China 5,400 4,564 14,037 11,930 Total contribution margin 35,156 35,080 103,919 99,326 Selling, general and administrative expenses (2) 31,643 32,926 97,339 95,098 Operating income 3,513 2,154 6,580 4,228 Other income (loss), net (353 ) 193 (1,420 ) 1,909 Income before provision for income taxes $ 3,160 $ 2,347 $ 5,160 $ 6,137 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in the NSP China segment related to sales in China, occurring after the Company’s receipt of its direct selling license and pre-opening product sales through Hong Kong, totaled $2.7 million and $6.7 million for the three and nine -month periods ended September 30, 2018 , respectively, compared to $2.1 million and $4.7 million for the three and nine -month periods ended September 30, 2017 . These service fees are included in the Company’s selling, general and administrative expenses. From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and nine -month periods ended September 30, 2018 and 2017 , as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Net sales: United States $ 33,182 $ 35,124 $ 101,322 $ 106,664 South Korea 18,271 14,371 52,463 38,203 Other 37,375 39,806 113,651 108,876 $ 88,828 $ 89,301 $ 267,436 $ 253,743 Net sales generated by each of the Company’s product lines is set forth below (dollar amounts in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 NSP Americas: General health $ 16,706 $ 18,211 $ 51,506 $ 56,258 Immune 4,304 4,938 13,693 13,180 Cardiovascular 3,000 3,434 8,974 9,570 Digestive 11,013 11,084 33,967 34,892 Personal care 1,735 2,114 5,070 5,487 Weight management 1,754 1,520 5,559 5,980 38,512 41,301 118,769 125,367 NSP Russia, Eastern and Central Europe: General health $ 3,632 $ 3,449 $ 11,883 $ 10,594 Immune 886 861 2,808 2,397 Cardiovascular 681 592 2,048 1,699 Digestive 2,196 2,110 7,137 6,348 Personal care 1,222 472 3,084 1,556 Weight management 224 197 839 692 8,841 7,681 27,799 23,286 Synergy WorldWide: General health $ 10,544 $ 9,268 $ 29,747 $ 23,579 Immune 57 119 346 357 Cardiovascular 14,798 14,369 43,511 38,075 Digestive 3,803 4,428 11,665 12,047 Personal care 1,520 1,891 5,968 5,884 Weight management 3,775 4,395 11,797 12,204 34,497 34,470 103,034 92,146 NSP China: General health $ 627 $ 1,151 $ 1,764 $ 2,470 Immune 156 179 312 310 Cardiovascular 850 911 3,259 2,368 Digestive 3,032 2,433 8,357 5,557 Personal care 1,128 115 2,388 184 Weight management 1,185 1,060 1,754 2,055 6,978 5,849 17,834 12,944 $ 88,828 $ 89,301 $ 267,436 $ 253,743 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): September 30, December 31, Property, plant and equipment: United States $ 62,504 $ 65,928 Other 3,027 3,178 Total property, plant and equipment $ 65,531 $ 69,106

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended September 30, 2018 and 2017 , the Company’s provision for income taxes, as a percentage of income before income taxes was 57.6 percent and 0.0 percent , respectively, compared with a U.S. federal statutory rate of 21.0 percent and 35.0 percent . For the nine months ended September 30, 2018 and 2017 , the Company’s provision for income taxes, as a percentage of income before income taxes was 68.8 percent and 38.2 percent , respectively, compared with a U.S. federal statutory rate of 21.0 percent and 35.0 percent . The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and nine months ended September 30, 2018 , was primarily attributed to current year foreign losses, largely related to China, that presently do not provide future tax benefit, as well as net unfavorable foreign items, partially offset by a decrease in the tax liability associated with uncertain tax positions. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended September 30, 2017, was primarily attributed to a decrease in the tax liability associated with uncertain tax positions, partially offset by current year foreign losses, largely related to China, that presently do not provide future tax benefit. The difference between the effective tax rate and the U.S. federal statutory tax rate for the nine months ended September 30, 2017, was primarily attributed to current year foreign losses, largely related to China, that presently do not provide future tax benefit, partially offset by foreign tax credit benefits as well as a decrease in tax liabilities associated with uncertain tax positions. In December 2017, the Tax Cuts and Jobs Act (Tax Reform Act) was signed into law. The provisions of the Tax Reform Act and related guidance provided by Staff Accounting Bulletin No. 118 allow for adjustments throughout 2018 to account for the impacts of the 2017 tax law changes. As of September 30, 2018, additional adjustments related to Global Intangible Low-taxed Income (GILTI) rules and the Foreign Derived Intangible Income (FDII) rules have been made. Furthermore, other adjustments may yet be necessary in future periods due to the significant complexity of the Tax Reform Act and anticipated additional regulatory guidance or technical corrections that may be forthcoming as well as actions the Company may take as a result of tax reform. The Company is continuing to gather additional information and expect to complete its accounting within one year of enactment. The Company’s U.S. federal income tax returns for 2015 through 2017 are open to examination for federal tax purposes. The Company has several foreign tax jurisdictions that have open tax years from 2011 through 2017. As of September 30, 2018 , the Company had accrued $2.2 million related to unrecognized tax positions, compared with $4.6 million as of December 31, 2017 . This net decrease was primarily attributed to changes in contingencies related to international tax. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although the Company believes its tax estimates are reasonable, the Company can make no assurance that the final tax outcome of these matters will not be different from that which it has reflected in its historical income tax provisions and accruals. Such differences could have a material impact on the Company’s income tax provision and operating results in the period in which the Company makes such determination.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings The Company is party to various legal proceedings. Management cannot predict the ultimate outcome of these proceedings, individually or in the aggregate, or their resulting effect on the Company’s business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. The Company maintains product liability, general liability and excess liability insurance coverage. However, no assurances can be given that such insurance will continue to be available at an acceptable cost to the Company, that such coverage will be sufficient to cover one or more large claims, or that the insurers will not successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies The Company has reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. The Company provides provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. The Company provides provisions for U.S. state sales taxes in each of the states where the Company has nexus. At September 30, 2018 and December 31, 2017 , accrued liabilities were $0.4 million and $0.4 million , respectively, related to non-income tax contingencies. While management believes that the assumptions and estimates used to determine this contingent liability are reasonable, the ultimate outcome of those matters cannot presently be determined. The Company believes future payments related to these matters could range from $0 to approximately $3.2 million . Other Litigation The Company is a party to various other legal proceedings in the United States and several foreign jurisdictions related to value-added tax assessments and other civil litigation. As of September 30, 2018 and December 31, 2017 , accrued liabilities were $1.6 million and $1.5 million , respectively, related to the estimated outcome of these proceedings. In addition, the Company is a party to other litigation where there is a reasonable possibility that a loss may be incurred, either the losses are not considered to be probable or the Company cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. The Company believes future payments related to these matters could range from $0 to approximately $1.9 million .

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions During the three and nine months ended September 30, 2018 , NSP China borrowed $2.0 million and $4.0 million from the Company and $0.5 million and $1.0 million the Company’s joint venture partner, respectively. These notes are payable in one year and bear interest of 3.0 percent . As of September 30, 2018 and December 31, 2017 outstanding borrowings by NSP China from the Company were $6.0 million and $2.0 million , respectively. As of September 30, 2018 and December 31, 2017 outstanding borrowings by NSP China from the Company’s joint venture partner were $1.5 million and $0.5 million , respectively. The notes between NSP China and the Company eliminate in consolidation.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of September 30, 2018 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,602 $ — $ — $ 1,602 Total assets measured at fair value on a recurring basis $ 1,602 $ — $ — $ 1,602 The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of December 31, 2017 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,980 $ — $ — $ 1,980 Total assets measured at fair value on a recurring basis $ 1,980 $ — $ — $ 1,980 Investment securities - trading — The Company’s trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the nine months ended September 30, 2018 , and for the year ended December 31, 2017 , there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying amount reflected on the condensed consolidated balance sheets for the revolving credit facility approximates fair value due to it being variable-rate debt. During the nine months ended September 30, 2018 and 2017 , the Company did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Revenue Recognition

Revenue Recognition	9 Months Ended
Revenue Recognition	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Adoption of ASU Topic 606 On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with the Company’s historic accounting under Topic 605. The Company recorded a net reduction to opening accumulated deficit of $0.9 million , net of tax, as of January 1, 2018 due to the cumulative impact of adopting Topic 606, with the impact primarily related to deferred revenue on shipments that had not been delivered being recognized upon shipment and deferrals for annual membership fees that are no longer deferred. The impact to revenues and operating income as a result of applying Topic 606 was a decrease of $0.5 million and $0.2 million , respectively, for the nine months ended September 30, 2018 . Revenue Recognition Net sales include products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. The Company recognizes revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of the Company’s contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. A reserve for product returns is recorded based upon historical experience and current trends. The Company allows independent Managers or Distributors to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of the Company’s markets, the requirements to return product are more restrictive. From time to time, the Company’s U.S. operations extend short-term credit associated with product promotions. In addition, for certain of the Company’s international operations, the Company offers credit terms consistent with industry standards within the country of operation. Volume incentives, and other sales incentives or rebates are a significant part of the Company’s direct sales marketing program, and represent commission payments made to independent distributors. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent Managers and Distributors for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Payments for sales incentives and rebates are calculated monthly based upon qualifying sales. Contract Liabilities - Customer Loyalty Programs The Company records contract liabilities for loyalty point programs in deferred revenue. These programs are accounted for as a reduction in the transaction price and are generally recognized as points are redeemed for additional products. The following table presents changes in these contract liability balances for the nine -month period ended September 30, 2018 (U.S. dollars in thousands): September 30, Outstanding at December 31, 2017 $ 1,126 Increase (decrease) attributed to: Customer loyalty net deferrals 3,538 Customer loyalty redemptions (3,342 ) Outstanding at September 30, 2018 $ 1,322 The table above excludes liability for sales returns, as they are insignificant. Disaggregation of Revenue The Company’s products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. The Company has four business segments that are divided based on the different characteristics of their distributor and customer bases, distributor compensation plans and product formulations. Three business segments operate under the Nature’s Sunshine Products brand and one business segment operates under the Synergy® WorldWide brand. See Note 8, Segment Information, for further information on the Company’s reportable segments and the Company’s presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions The Company has made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606. The Company generally expenses volume incentives when incurred because the amortization period would have been one year or less. All of the Company’s contracts with customers have a duration of less than one year, the value of any unsatisfied performance obligations is insignificant.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Nature’s Sunshine Products, Inc., together with its subsidiaries (hereinafter referred to collectively as the “Company”), is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent distributors who use the products themselves or resell them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The Company consolidates the joint ventures in Hong Kong and China in its consolidated financial statements, with another party’s interest presented as noncontrolling interest. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the Company’s financial information as of September 30, 2018 , and for the three and nine -month periods ended September 30, 2018 and 2017 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2018 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 .
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests decreased as a result of the net loss attributable to the noncontrolling interests by $0.5 million and $0.6 million during the nine months ended September 30, 2018 and 2017 , respectively. As of September 30, 2018 and December 31, 2017 , noncontrolling deficits were $41,000 and noncontrolling interests were $0.4 million , respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company adopted the requirements of revenue recognition from Accounting Standards Update ( “ ASU ” ) 2014-09, Revenue from Contracts with Customers (“Topic 606”) effective January 1, 2018 under the modified retrospective approach. The cumulative effect of adopting Topic 606 on January 1, 2018 was a decrease to accumulated deficit of $0.9 million (net of tax). See Note 13 - Revenue Recognition for additional disclosure of the adoption of Topic 606. In January 2016, the Financial Accounting Standards Board ( “ FASB ” ) issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure requirements associated with the fair value of financial instruments. This update is effective for interim and annual periods beginning after December 15, 2017. The adoption of this ASU did not have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842): Accounting for Leases. This update specifies that lessees should recognize right-of-use assets and lease liabilities arising from leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and shall continue to depend on its classification as a finance or operating lease. The Company will adopt the ASU and related amendments on January 1, 2019 and expects to elect certain practical expedients permitted under the transition guidance. The Company will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and will not restate prior periods. Under the new guidance, the majority of the Company's leases will continue to be classified as operating. The Company continues to evaluate the potential impact of adoption of this ASU on its consolidated financial statements, and expects a significant gross-up of total assets and liabilities upon adoption. The adoption of this ASU is not expected to have a significant impact on the Company's Consolidated Statements of Income or Cash Flows. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update amends the scope of modification accounting surrounding share-based payment arrangements as issued in ASU 2016-09 by providing guidance on the various types of changes which would trigger modification accounting for share-based payment awards. ASU 2017-09 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The adoption of ASU 2017-09 did not have a material effect on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Effects from Accumulated Other Comprehensive Income. This update allows a reclassification of stranded tax effects, resulting from the Tax Cuts and Jobs Act 2017, from accumulated other comprehensive income to retained earnings. This ASU will be effective for annual periods beginning after December 15, 2018 with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the potential impact of this adoption on its condensed consolidated financial statements.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): September 30, December 31, Raw materials $ 10,625 $ 9,522 Work in progress 1,937 2,153 Finished goods 30,479 32,372 Total inventories $ 43,041 $ 44,047

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
Net Income Per Share (Tables)	Sep. 30, 2018
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and nine months ended September 30, 2018 and 2017 (dollar and share amounts in thousands, except for per share information): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Net income attributable to common shareholders $ 1,497 $ 2,443 $ 2,062 $ 4,416 Basic weighted average shares outstanding 19,164 18,897 19,094 18,873 Basic earnings per share attributable to common shareholders $ 0.08 $ 0.13 $ 0.11 $ 0.23 Diluted shares outstanding: Basic weighted-average shares outstanding 19,164 18,897 19,094 18,873 Stock-based awards 218 389 312 392 Diluted weighted-average shares outstanding 19,382 19,286 19,406 19,265 Diluted earnings per share attributable to common shareholders $ 0.08 $ 0.13 $ 0.11 $ 0.23 Dilutive shares excluded from diluted-per-share amounts: Stock options 105 294 105 294 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options 1,036 1,309 1,011 1,309

Capital Transactions (Tables)

Capital Transactions (Tables)	9 Months Ended
Capital Transactions (Tables)	Sep. 30, 2018
Equity [Abstract]
Schedule of stock option activity	Stock option activity for the nine -month period ended September 30, 2018 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2017 1,390 $ 12.20 Granted 50 8.43 Forfeited or canceled (227 ) 13.87 Exercised (99 ) 6.10 Options outstanding at September 30, 2018 1,114 12.23
Schedule of restricted stock unit activity	RSU activity for the nine -month period ended September 30, 2018 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2017 728 $ 11.56 Granted 511 9.93 Forfeited (103 ) 12.17 Issued (243 ) 11.77 Restricted Stock Units outstanding at September 30, 2018 893 10.50

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
Segment Information (Tables)	Sep. 30, 2018
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Net sales: NSP Americas $ 38,512 $ 41,301 $ 118,769 $ 125,367 NSP Russia, Central and Eastern Europe 8,841 7,681 27,799 23,286 Synergy WorldWide 34,497 34,470 103,034 92,146 NSP China 6,978 5,849 17,834 12,944 Total net sales 88,828 89,301 267,436 253,743 Contribution margin (1): NSP Americas 17,006 17,764 49,530 53,454 NSP Russia, Central and Eastern Europe 3,098 2,592 9,437 6,173 Synergy WorldWide 9,652 10,160 30,915 27,769 NSP China 5,400 4,564 14,037 11,930 Total contribution margin 35,156 35,080 103,919 99,326 Selling, general and administrative expenses (2) 31,643 32,926 97,339 95,098 Operating income 3,513 2,154 6,580 4,228 Other income (loss), net (353 ) 193 (1,420 ) 1,909 Income before provision for income taxes $ 3,160 $ 2,347 $ 5,160 $ 6,137 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in the NSP China segment related to sales in China, occurring after the Company’s receipt of its direct selling license and pre-opening product sales through Hong Kong, totaled $2.7 million and $6.7 million for the three and nine -month periods ended September 30, 2018 , respectively, compared to $2.1 million and $4.7 million for the three and nine -month periods ended September 30, 2017 . These service fees are included in the Company’s selling, general and administrative expenses.
Schedule of consolidated net sales revenue by geographical locations	From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and nine -month periods ended September 30, 2018 and 2017 , as follows (dollar amounts in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 Net sales: United States $ 33,182 $ 35,124 $ 101,322 $ 106,664 South Korea 18,271 14,371 52,463 38,203 Other 37,375 39,806 113,651 108,876 $ 88,828 $ 89,301 $ 267,436 $ 253,743
Schedule of revenue generated by each of the Company's product lines	Net sales generated by each of the Company’s product lines is set forth below (dollar amounts in thousands): Three Months Ended Nine Months Ended 2018 2017 2018 2017 NSP Americas: General health $ 16,706 $ 18,211 $ 51,506 $ 56,258 Immune 4,304 4,938 13,693 13,180 Cardiovascular 3,000 3,434 8,974 9,570 Digestive 11,013 11,084 33,967 34,892 Personal care 1,735 2,114 5,070 5,487 Weight management 1,754 1,520 5,559 5,980 38,512 41,301 118,769 125,367 NSP Russia, Eastern and Central Europe: General health $ 3,632 $ 3,449 $ 11,883 $ 10,594 Immune 886 861 2,808 2,397 Cardiovascular 681 592 2,048 1,699 Digestive 2,196 2,110 7,137 6,348 Personal care 1,222 472 3,084 1,556 Weight management 224 197 839 692 8,841 7,681 27,799 23,286 Synergy WorldWide: General health $ 10,544 $ 9,268 $ 29,747 $ 23,579 Immune 57 119 346 357 Cardiovascular 14,798 14,369 43,511 38,075 Digestive 3,803 4,428 11,665 12,047 Personal care 1,520 1,891 5,968 5,884 Weight management 3,775 4,395 11,797 12,204 34,497 34,470 103,034 92,146 NSP China: General health $ 627 $ 1,151 $ 1,764 $ 2,470 Immune 156 179 312 310 Cardiovascular 850 911 3,259 2,368 Digestive 3,032 2,433 8,357 5,557 Personal care 1,128 115 2,388 184 Weight management 1,185 1,060 1,754 2,055 6,978 5,849 17,834 12,944 $ 88,828 $ 89,301 $ 267,436 $ 253,743
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): September 30, December 31, Property, plant and equipment: United States $ 62,504 $ 65,928 Other 3,027 3,178 Total property, plant and equipment $ 65,531 $ 69,106

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of the Company's hierarchy for assets measured at fair value on a recurring basis	The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of September 30, 2018 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,602 $ — $ — $ 1,602 Total assets measured at fair value on a recurring basis $ 1,602 $ — $ — $ 1,602 The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of December 31, 2017 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,980 $ — $ — $ 1,980 Total assets measured at fair value on a recurring basis $ 1,980 $ — $ — $ 1,980

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
Revenue Recognition (Tables)	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	The following table presents changes in these contract liability balances for the nine -month period ended September 30, 2018 (U.S. dollars in thousands): September 30, Outstanding at December 31, 2017 $ 1,126 Increase (decrease) attributed to: Customer loyalty net deferrals 3,538 Customer loyalty redemptions (3,342 ) Outstanding at September 30, 2018 $ 1,322 The table above excludes liability for sales returns, as they are insignificant.

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Basis of Presentation (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Noncontrolling Interest [Line Items]
Decrease in noncontrolling interest		$ 500	$ 600
Noncontrolling interest (deficit)	$ (41)	(41)		$ 411
Transition expenses	17	1,500
Accrued transition costs	1,100	1,100
Retained earnings (accumulated deficit)	844	844		(2,072)
Accrued Severance and Rent Costs
Noncontrolling Interest [Line Items]
Accrued severance and rent costs	$ 300	$ 300		800
Difference between Revenue Guidance in Effect before and after Topic 606 \| Accounting Standards Update 2014-09
Noncontrolling Interest [Line Items]
Retained earnings (accumulated deficit)				$ 900

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 10,625	$ 9,522
Work in progress	1,937	2,153
Finished goods	30,479	32,372
Total inventories	$ 43,041	$ 44,047

Property, Plant and Equipment (

Property, Plant and Equipment (Details)	1 Months Ended		3 Months Ended	9 Months Ended
Property, Plant and Equipment (Details)	Aug. 31, 2018USD ($)a	Jun. 30, 2018USD ($)ft²	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Property, Plant and Equipment [Line Items]
Proceeds from sale of property, plant and equipment				$ 5,072,000	$ 522,000
Gain on sale of property				4,000,000	$ 0
Provo, Utah
Property, Plant and Equipment [Line Items]
Number of acres \| a	8
Impairment of long-lived assets held-for-use			$ 1,700,000	1,700,000
Proceeds from sale of property, plant and equipment	$ 2,700,000
Mexico City, Mexico
Property, Plant and Equipment [Line Items]
Number of square feet \| ft²		29,300
Proceeds from sale of property, plant and equipment		$ 2,600,000
Gain on sale of property			$ 0	$ 2,300,000

Investment Securities - Tradi_2

Investment Securities - Trading (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Trading securities portfolio	$ 1,602		$ 1,602		$ 1,980
Debt securities, trading, realized gain	$ 70	$ 51	$ 103	$ 102

Revolving Credit Facility (Deta

Revolving Credit Facility (Details) - Revolving credit facility - Bank of America Credit Agreement - USD ($)	Jul. 11, 2017	Sep. 30, 2018	Dec. 31, 2017
Long-term debt
Maximum borrowing capacity	$ 25,000,000
Annual commitment fee	0.20%
Long-term line of credit		$ 1,800,000
LIBOR
Long-term debt
Margin on variable rate	1.25%
Effective interest rate		3.49%	2.82%

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Net income attributable to common shareholders	$ 1,497	$ 2,443	$ 2,062	$ 4,416
Basic weighted-average shares outstanding (in shares)	19,164	18,897	19,094	18,873
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.08	$ 0.13	$ 0.11	$ 0.23
Diluted shares outstanding:
Basic weighted-average shares outstanding (in shares)	19,164	18,897	19,094	18,873
Stock-based awards (in shares)	218	389	312	392
Diluted weighted-average shares outstanding (in shares)	19,382	19,286	19,406	19,265
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.08	$ 0.13	$ 0.11	$ 0.23
Dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	105	294	105	294
Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	1,036	1,309	1,011	1,309

Capital Transactions - Narrativ

Capital Transactions - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Capital Transactions - Narrative (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2012
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)							1,500,000
Additional number of shares authorized under the plan (in shares)					1,500,000
Maximum \| 2009 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)	400,000		400,000
Time-based stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 100,000	$ (200,000)	$ 200,000	$ 200,000
Unrecognized share-based compensation expense	$ 0		$ 0			$ 13,000
Time-based stock options \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			50,000
Exercised (in dollars per share)			$ 8.43
Weighted-average grant date fair value (in dollars per share)			$ 3.30
Expected contractual life (in years)			5 years
Risk-free interest rate (as a percent)			2.80%
Expected volatility (as a percent)			38.80%
Time-based stock options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			48 months
Performance based stock options operating income margins
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Operating income margin, one (as a percent)			6.00%
Operating income margin, two (as a percent)			8.00%
Operating income margin, three (as a percent)			10.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			50,000
Exercised (in dollars per share)			$ 6.10	$ 11.98
Options outstanding (in shares)	1,114,000		1,114,000			1,390,000
Aggregate intrinsic value, outstanding	$ 300,000		$ 300,000			$ 900,000
Exercisable (in shares)						1,293,000
Expected to vest (in shares)						92,000
Aggregate intrinsic value, exercisable						$ 900,000
Aggregate intrinsic value, expected to vest						0
Exercised (in shares)			99,000	9,000
Aggregate intrinsic values of options exercised			$ 400,000	$ 200,000
Tax benefit from the exercise of stock options			100,000	0
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	300,000	$ 300,000	1,300,000	1,700,000
Unrecognized share-based compensation expense	$ 2,400,000		$ 2,400,000			$ 2,000,000
Discount for lack of marketability			11.90%
Weighted-average period over which the remaining compensation cost is expected to be recognized			1 year 6 months
Minimum withholding requirements (in shares)			55,000
RSUs \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			511,000
RSUs \| Maximum \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			48 months
RSUs \| Minimum \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			12 months
RSUs \| Director \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restriction period for issuance of shares			2 years
Nonvested subject to restriction period (in shares)	71,000		71,000			96,000
Performance-Based Restricted Stock Units (RSUs), Net Sales Growth Target \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Performance-Based Restricted Stock Units (RSUs), Earnings Per Share Achievement \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Earnings per share target period			45 days
Performance-Based Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 0	$ 0
Performance-Based Restricted Stock Units (RSUs) \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)			$ 9.79
Performance-Based Restricted Stock Units (RSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation potential compensation expense to be recognized	$ 4,700,000		$ 4,700,000
Performance-Based Restricted Stock Units (RSUs) \| Net Sales and Operating Income Targets \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Time-Based Restricted Stock Units (RSUs) \| 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Weighted-average grant date fair value (in dollars per share)			$ 10.16

Capital Transactions - Stock Op

Capital Transactions - Stock Option Activity (Details) - Stock options - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Number of Shares
Options outstanding at the beginning of the period (in shares)	1,390,000
Granted (in shares)	50,000
Forfeited or canceled (in shares)	(227,000)
Exercised (in shares)	(99,000)	(9,000)
Options outstanding at the end of the period (in shares)	1,114,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)	$ 12.20
Granted (in dollars per share)	8.43
Forfeited or canceled (in dollars per share)	13.87
Exercised (in dollars per share)	6.10	$ 11.98
Options outstanding at the end of the period (in dollars per share)	$ 12.23

Capital Transactions - RSU Acti

Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Shares
Restricted Stock Units outstanding, beginning balance (in shares) \| shares	728,000
Granted (in shares) \| shares	511,000
Issued (in shares) \| shares	(103,000)
Forfeited (in shares) \| shares	(243,000)
Restricted Stock Units outstanding, ending balance (in shares) \| shares	893,000
Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding, beginning balance (in dollars per share) \| $ / shares	$ 11.56
Granted (in dollars per share) \| $ / shares	9.93
Issued (in dollars per share) \| $ / shares	12.17
Forfeited (in dollars per share) \| $ / shares	11.77
Restricted Stock Units outstanding, ending balance (in dollars per share) \| $ / shares	$ 10.50

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
Segment Information (Details) $ in Thousands	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)segment	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Segment information
Number of business segments \| segment			4
Net sales:
Total net sales revenue	$ 88,828	$ 89,301	$ 267,436	$ 253,743
Contribution margin:
Total contribution margin	35,156	35,080	103,919	99,326
Selling, general and administrative expenses	31,643	32,926	97,339	95,098
Operating income	3,513	2,154	6,580	4,228
Other income (loss), net	(353)	193	(1,420)	1,909
Income before provision for income taxes	3,160	2,347	5,160	6,137
Property, plant and equipment:
Total property, plant and equipment	65,531		65,531		$ 69,106
United States
Net sales:
Total net sales revenue	33,182	35,124	101,322	106,664
Property, plant and equipment:
Total property, plant and equipment	62,504		62,504		65,928
South Korea
Net sales:
Total net sales revenue	18,271	14,371	52,463	38,203
Other Countries
Net sales:
Total net sales revenue	37,375	39,806	113,651	108,876
Other
Property, plant and equipment:
Total property, plant and equipment	3,027		$ 3,027		$ 3,178
NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China
Segment information
Number of operating segments \| segment			3
NSP Americas
Net sales:
Total net sales revenue	38,512	41,301	$ 118,769	125,367
Contribution margin:
Total contribution margin	17,006	17,764	49,530	53,454
NSP Americas \| General health
Net sales:
Total net sales revenue	16,706	18,211	51,506	56,258
NSP Americas \| Immune
Net sales:
Total net sales revenue	4,304	4,938	13,693	13,180
NSP Americas \| Cardiovascular
Net sales:
Total net sales revenue	3,000	3,434	8,974	9,570
NSP Americas \| Digestive
Net sales:
Total net sales revenue	11,013	11,084	33,967	34,892
NSP Americas \| Personal care
Net sales:
Total net sales revenue	1,735	2,114	5,070	5,487
NSP Americas \| Weight management
Net sales:
Total net sales revenue	1,754	1,520	5,559	5,980
NSP Russia, Central and Eastern Europe
Net sales:
Total net sales revenue	8,841	7,681	27,799	23,286
Contribution margin:
Total contribution margin	3,098	2,592	9,437	6,173
NSP Russia, Central and Eastern Europe \| General health
Net sales:
Total net sales revenue	3,632	3,449	11,883	10,594
NSP Russia, Central and Eastern Europe \| Immune
Net sales:
Total net sales revenue	886	861	2,808	2,397
NSP Russia, Central and Eastern Europe \| Cardiovascular
Net sales:
Total net sales revenue	681	592	2,048	1,699
NSP Russia, Central and Eastern Europe \| Digestive
Net sales:
Total net sales revenue	2,196	2,110	7,137	6,348
NSP Russia, Central and Eastern Europe \| Personal care
Net sales:
Total net sales revenue	1,222	472	3,084	1,556
NSP Russia, Central and Eastern Europe \| Weight management
Net sales:
Total net sales revenue	224	197	$ 839	692
Synergy WorldWide
Segment information
Number of operating segments \| segment			1
Net sales:
Total net sales revenue	34,497	34,470	$ 103,034	92,146
Contribution margin:
Total contribution margin	9,652	10,160	30,915	27,769
Synergy WorldWide \| General health
Net sales:
Total net sales revenue	10,544	9,268	29,747	23,579
Synergy WorldWide \| Immune
Net sales:
Total net sales revenue	57	119	346	357
Synergy WorldWide \| Cardiovascular
Net sales:
Total net sales revenue	14,798	14,369	43,511	38,075
Synergy WorldWide \| Digestive
Net sales:
Total net sales revenue	3,803	4,428	11,665	12,047
Synergy WorldWide \| Personal care
Net sales:
Total net sales revenue	1,520	1,891	5,968	5,884
Synergy WorldWide \| Weight management
Net sales:
Total net sales revenue	3,775	4,395	11,797	12,204
NSP China
Net sales:
Total net sales revenue	6,978	5,849	17,834	12,944
Contribution margin:
Total contribution margin	5,400	4,564	14,037	11,930
NSP China \| General health
Net sales:
Total net sales revenue	627	1,151	1,764	2,470
NSP China \| Immune
Net sales:
Total net sales revenue	156	179	312	310
NSP China \| Cardiovascular
Net sales:
Total net sales revenue	850	911	3,259	2,368
NSP China \| Digestive
Net sales:
Total net sales revenue	3,032	2,433	8,357	5,557
NSP China \| Personal care
Net sales:
Total net sales revenue	1,128	115	2,388	184
NSP China \| Weight management
Net sales:
Total net sales revenue	1,185	1,060	1,754	2,055
NSP China \| Hong Kong
Contribution margin:
Selling, general and administrative expenses	$ 2,700	$ 2,100	$ 6,700	$ 4,700

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	57.60%	0.00%	68.80%	38.20%
Liability related to unrecognized tax benefits	$ 2.2		$ 2.2		$ 4.6

Commitments and Contingencies (

Commitments and Contingencies (Details)	9 Months Ended
Commitments and Contingencies (Details)	Sep. 30, 2018USD ($)claim	Dec. 31, 2017USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover \| claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	400,000	$ 400,000
Minimum \| Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum \| Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum \| Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	1,900,000
Maximum \| Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	3,200,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 1,600,000	$ 1,500,000

Related Party Transactions (Det

Related Party Transactions (Details) - NSP China - Subsidiaries - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Notes receivable, related parties, current	$ 6	$ 6	$ 2
Company's Joint Venture Partner
Related Party Transaction [Line Items]
Notes receivable, related parties, current	1.5	1.5	$ 0.5
Notes Receivable
Related Party Transaction [Line Items]
Related party transaction, amount	2	$ 4
Related party transaction, rate		3.00%
Notes Receivable \| Company's Joint Venture Partner
Related Party Transaction [Line Items]
Related party transaction, amount	$ 0.5	$ 1

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring basis - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Total
Fair value
Investment securities - trading	$ 1,602	$ 1,980
Total assets measured at fair value on a recurring basis	1,602	1,980
Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Investment securities - trading	1,602	1,980
Total assets measured at fair value on a recurring basis	1,602	1,980
Level 2 - Significant Other Observable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	0	0
Level 3 - Significant Unobservable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	$ 0	$ 0

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
Revenue Recognition - Narrative (Details) $ in Thousands	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)segmentproduct_category	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Retained earnings (accumulated deficit)	$ 844		$ 844		$ (2,072)
Decrease in revenue	(88,828)	$ (89,301)	(267,436)	$ (253,743)
Decrease in operating income	(3,513)	(2,154)	$ (6,580)	(4,228)
Refund period			90 days
Number of principal categories of products \| product_category			6
Number of business segments \| segment			4
NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of operating segments \| segment			3
Synergy WorldWide
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Decrease in revenue	$ (34,497)	$ (34,470)	$ (103,034)	$ (92,146)
Number of operating segments \| segment			1
Accounting Standards Update 2014-09 \| Difference between Revenue Guidance in Effect before and after Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Retained earnings (accumulated deficit)					$ 900
Decrease in revenue			$ 500
Decrease in operating income			$ 200

Revenue Recognition - Changes i

Revenue Recognition - Changes in Contract Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Change in Contract with Customer, Liability [Roll Forward]
Outstanding at December 31, 2017	$ 1,126
Increase (decrease) attributed to:
Customer loyalty net deferrals	3,538
Customer loyalty redemptions	(3,342)
Outstanding at September 30, 2018	$ 1,322